Source comparison
SS-31 Research Review: Model Comparison
Ischemia-reperfusion injury (rat heart) Infarct size reduction 3 mg/kg IV pre-ischemia 50–60% smaller infarcts vs saline; preserved cristae structure on electron microscopy Pre-treatment timing critical; post-ischemia efficacy reduced by 70% when delayed >30 m
This comparison does not assign a generated winner or score.
- Ischemia-reperfusion injury (rat heart)
- Infarct size reduction
- 3 mg/kg IV pre-ischemia
- 50–60% smaller infarcts vs saline; preserved cristae structure on electron microscopy
- Pre-treatment timing critical; post-ischemia efficacy reduced by 70% when delayed >30 min
- Barth syndrome (human phase 2 RCT)
- Six-minute walk distance
- 0.25 mg/kg/hour IV for 12 weeks
- +48 meters vs baseline (p<0.05); +13.2% ATP flux in skeletal muscle
- First human trial showing functional improvement in genetic mitochondrial disease
- HFpEF (PROGRESS-HF phase 2)
- LV end-diastolic volume
- 4 mg/hour IV infusion
- No overall effect; subgroup with NT-proBNP >600 pg/mL showed improved diastolic function
- Benefit limited to patients with more severe mitochondrial impairment at baseline
- Alzheimer's disease (APP/PS1 mice)
- Hippocampal amyloid plaque burden
- 5 mg/kg IP daily for 4 months
- Reduced plaque burden, preserved synaptic density, improved spatial memory
- Mitochondrial protection may prevent downstream amyloid pathology
- Renal ischemia-reperfusion (mouse model)
- Tubular necrosis and fibrosis
- 3 mg/kg IP immediately post-injury
- 40% less fibrosis at 28 days; preserved GFR
- Early intervention prevents chronic progression after acute injury
- Exercise capacity in aged mice
- Treadmill running distance
- 3 mg/kg IP daily for 8 weeks
- +25–30% running distance; improved mitochondrial RCR without biogenesis increase
- Function restoration without new mitochondria synthesis